FDA Approves First DNA Medicine, VOCERYQ, to Reduce Surgeries in Adults with RRP

INOVIO’s VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis.